

Index

Page numbers followed by f denote figures; page numbers followed by t denote tables.

- AAR ligands, 206
- ABI 3700 capillary-array-based DNA sequencing system, 19
- ABI PRISM 377 Automated DNA Sequencer, 19
- Acceptable daily intake (ADI), 436–438
- ACE inhibitors, 278–279
- Acetylation, incidence of, 141–143
- Acetylation reactions, 139
- Acetylcholinesterase (AChE), 169
- Acquired immunodeficiency syndrome (AIDS), 314–315. *See also* Human immunodeficiency virus (HIV) susceptibility to, 315
- Acrylamide slab-gel-based platform, 18
- Addiction
 - biologic aspects of, 354–359
 - defining phenotypes in, 352
 - future investigations of, 371–372
 - gene–environment interactions in, 352
 - genetic determinants of, 351–373, 359–371
 - genetic epidemiology of, 353–354
- Additive interaction models, 279–281
- Additive model, 85–86
- Adenocarcinoma, esophageal, 240
- ADHIB gene, 359
- Adoption studies, of addiction, 353–354
- Adrenergic receptors, 198–201
 - β_1 , 200
 - β_2 , 200, 201
 - physiologic responses and functions of, 199
 - polymorphisms of, 199t, 200–201
- Adult lactase persistence, 334–336
- “Adult-onset” diabetes mellitus, 286
- Adult phenotype, developmental epigenetic determinants of, 325–328
- Adverse health effect, defining, 430–431
- AFB₁-albumin adduct formation, 346
- Aflatoxin, 346–347
- Aggregation studies, 77–79
- AGT expression, 182
- AHR-ARNT dimer, 102. *See also* Ah receptor nuclear translocator (ARNT)
- Ah receptor nuclear translocator (ARNT), 205. *See also* AHR-ARNT dimer; Aryl hydrocarbon (Ah) receptor
- AIDS-defining illnesses, 314–315
- Alcohol
 - metabolic pathway of, 355
 - role in esophageal cancer, 245–247
- Alcohol challenge studies, 354

- Alcohol dehydrogenase (ADH)
system, 359
- Alcohol dependence
adoption studies on, 353–354
GABA system and, 364
genetic determinants of, 359–365
treatment of, 364, 372
twin studies on, 354
- Alcohol disorders, studies of potential
genetic determinants of, 360t
- Alcoholic liver disease, CYP2E1
metabolic activity and, 111–112
- Aldehyde dehydrogenase (ALDH2),
246–247
- Aldehyde dehydrogenase (ALDH)
system, 359–361
- Aldicarb, toxicity of, 119–120
- Alkylation damage, 181–182
- Alkyltransferases, 182
- Allele frequencies, estimating, 75
- Alleles
dependence between, 76
identical by descent, 81–82
- Allele-specific PCR (AS-PCR), 25
- Allergy, food, 329–330
- Aluminum, role in Alzheimer's disease,
256
- Alzheimer's disease (AD), 253,
254–259
ApoE and, 259
BChE and, 173
candidate genes in, 257–258
environmental risk factors in,
256–257
estrogen receptors and, 205
pathogenesis of, 254–256
- Americans with Disabilities Act
(ADA), 420–422
- Amino acid metabolism, genetic
differences in, 331–334
- Amino acid metabolism disorders,
dietary adjustments for, 332t
- Amyotrophic lateral sclerosis (ALS),
253, 264–265
candidate genes in, 265
- Analysis, of microarray data, 44–47
- Analysis programs, commercial, 46
- Anderson, Jon P., xiii, 179
- Angiotensinogen (ATG), 278
- Animal bioassays, 432–433
- Animal models
of infectious disease, 306–307
of malaria, 313
- Annealing, in polymerase chain
reaction, 20
- Antabuse, 372
- Antidiscrimination legislation, 416
- Antihypertensive medications,
variation in response to, 278
- Antioxidant response elements
(AREs), 155–156
- Antisense primer, 20
- APE1 endonuclease, 184
- APOE gene, 339. *See also*
Apolipoprotein E (ApoE)
linkage disequilibrium and, 281–282
single nucleotide polymorphisms in,
282
- APOE genotypes, cardiovascular
disease and, 276
- Apolipoprotein E (ApoE), 257–259,
339. *See also* APOE entries
Alzheimer's disease and, 259
gene–environment interactions with,
258–259
- Apolipoprotein structural genes,
275–276
- Applied Biosystems' automated DNA
sequencer platform, 26
- Arg389Gly polymorphism, 200
- Arg554Lys coding variant, 103
- Aromatic amines, 105, 431
- Aromatic hydrocarbon (AH) receptor,
102–103
- Aromatic hydrocarbons (AHs),
103–104
- Array-based CGH, 32
- Array manufacturers, commercial, 41
- Arsenic exposure, type 2 diabetes and,
289–290

- Aryl hydrocarbon (Ah) receptor, 205–207
- Association methods, population-based, 83
- Association studies, of type 2 diabetes, 294–295
- Association tests, 85
- Asthma, beta₂ agonists and, 201
- Asthma case study, 385–387
- Asthma genomics, potential applications of, 386t
- Asthma prevention
ethical analysis of, 388–391
responsibility for, 393
- Asthma research, ethics tools for issues raised by, 387–391
- Atopy genes, 329–330
- “At risk” populations, 434–435
- Austin, Melissa A., xiii, 271
- Automated DNA sequencers, 26
- Automated sequence detection systems, 35–36
- Bammler, Theo K., xiii, 17, 127
- Barrett’s esophagus, 243
- Base excision repair (BER), 182–185
lung cancer and, 230–231
- Battuello, Kate, xiii, 411
- BChE polymorphisms, 170–172. *See also* Butyrylcholinesterase (BChE)
- Benchmark dose (BMD) approaches, 440
- Benzene poisoning, 111
- Beresford, Shirley, xiii, 397
- Berylliosis, 58–59
- Beryllium
exposure to, 404–405, 443
research program on, 414
- β₁ adrenergic receptors, 200
- β₂ adrenergic receptors, 200, 201
- β-ahydroxylase, 370
- Beyer, Richard P., xiii, 17
- Bhatti, Parveen, xiii, 51
- Bias, in epidemiologic research, 59–64
- “Bias toward the null,” 62
- Bioassays, animal, 432–433
- Biochemical individuality, 9
- Biochemical insult, predisposition for, 328
- Biochemistry of Genetics, The* (Haldane), 8
- Bioconductor, 44–45, 46
- Bioethics, principles in, 378, 382
- Biological interpretation, 46–47
- Biological replication, 43–44
- Biologic sample banking, 55
- Biomarker paradigm, 436–444
- Biomarkers, 14
of effect, 441
of exposure, 441
of susceptibility, 441–442
types of, 441–442
- Biopsychosocial health determinants, 398, 399t
- Biotransformation, in xenobiotic detoxification and elimination, 95–96
- Biotransformation enzymatic activity, genetic variability in, 345
- Biotransformation enzyme combinations, lung cancer and, 231–233
- Biotransformation enzymes, 91–92, 325
phase I, 92
phase II, 93
polymorphisms in, 218–229, 345–347
- Biotransformation reactions, categories of, 127
- Bitter taste, sensitivity to, 328–329
- Bladder cancer, 143
GSTM1 null genotype and, 153
- BLAST sequence analysis, 21
- Blood contamination, HIV, 315
- Blood pressure, Arg389Gly polymorphism and, 200
- Bone mineral density, VDR polymorphisms and, 203
- Bowen, Deborah, xiii, 397
- Brain reward pathway, 356

- Branched-chain ketoacid dehydrogenase, 333–334
- Branched-chain ketoaciduria, 333–334
- Breast cancer, 57–58, 125
- estrogen receptors and, 205
 - familial, 443
 - GSTM1 genotype and, 153
 - non-homologous end joining and, 190
- Bronchospasm, beta₂ agonists and, 201
- Buprenorphine, 368
- Burke, Wylie, xiii, 381
- Butyrylcholinesterase (BChE), 159, 168–173. *See also* BChE polymorphisms
- as an ecogenetic marker, 169–170
 - environmental toxins and, 172–173
 - gene and protein structure of, 170
 - major genetic variants of, 171
 - role in neurodegenerative diseases, 173
- Bypass polymerases, 192–193
- Bypass synthesis mechanism, 192
- Calcium absorption, 341–342
- Cancer(s). *See also* Esophageal cancer(s); Gastric cancer; Gastrointestinal (GI) cancers; Lung cancer entries; Mutator phenotype; Prostate cancer; Rectal cancer; Squamous cell carcinoma; Stomach cancer
- cruciferous vegetables and, 349
 - CYP1B1 and, 107
 - CYP2E1 polymorphisms and, 111
 - DNA repair and, 229–231
 - DNA repair gene polymorphisms and, 193
 - estrogen receptors and, 204
 - gene amplification and, 31
 - GSTM1 polymorphism and, 153
 - meat intake and, 345
 - smoking-related, 153
 - tobacco-related, 109
 - VDR polymorphisms and, 203
- Cancer bioassays, 432
- Cancer progression, mutator phenotype in, 195f
- Cancer research, gene expression profiling and, 47–48
- Cancer risk, NAT polymorphisms and, 143
- Candidate genes, selection of, 268–269
- Cannabinoid receptors, 358
- Cannabis use, genetic determinants of, 370–371
- Capillary-array-based platforms, 19
- CAPN10 gene, 295–296
- Carbohydrate metabolism, genetic differences in, 334–337
- Carcinogenesis, 194, 216
- Carcinogens, genetic differences in metabolism of, 345–347
- Cardiovascular disease (CVD), 271–283. *See also* CVD entries
- beta₂-adrenergic receptor polymorphisms and, 201
 - case–control studies in, 273–275
 - experimental studies in, 276–278
 - pharmacogenomics in, 278–279
 - prospective studies in, 275–276
- Cardiovascular ecogenetics, special topics in, 278–282
- Carlsten, Christopher R., xiii, 381
- Case–control studies, 55–58
- in cardiovascular disease, 273–275
 - data layout for, 56f
 - questionnaire response validity in, 64
- Case-only study design, 68, 299
- Case-parent study design, 68, 299–300
- Catalytic receptors, 197
- Catechol *o*-methyltransferase (COMT), 143–146
- Caucasian populations, CYP2D6 in, 221–222
- Causal genes, challenges of mapping, 273
- Causation, in toxic tort litigation, 423

- CB1 cannabinoid receptor, 370–371
 CB1 receptor gene, cocaine dependence and, 370
 CCR5-Δ32 allele, 316
 CCR5 mutations, 316
 cDNA arrays, 49
 effect on mRNA level measurement, 39–40
 cDNA-based microarrays, 33–34, 37–40
 Celiac disease, 330–331
 Cell repair mechanisms, 181–193
 Cell surface receptors, 197
 Cerebral malaria, 313
 Channel-linked receptors, 197
 Channelopathies, 209
 Checkoway, Harvey, xiii, 51, 253
 Chemical laws, 445t
 Chemicals
 CYP-mediated oxidation of, 92
 toxic effects of, 93
 Chemical weapons, BChE mutations and, 172
 Chemokines, HIV infection and, 316–317
 Chemotherapy, in lung cancer, 233
Chevron v. Echazabal, 421–422
 Cholesterol
 ApoE interactions with, 258
 levels of, 275–276
 Cholinesterases, forms of, 168–169
 Chromosome 21 study, 281
 Chronic beryllium disease (CBD), 383–385, 404–405, 443
 Cigarette smoke, 216
 Cigarette smoking, esophageal squamous cell carcinoma and, 242. *See also* Nicotine entries; Smoking entries; Tobacco entries
 Clean Air Act of 1970 (CAA), 14
 amendments to, 446
 Clinical implications, of ecogenetics, 15–16
 Clinical Laboratory Improvement Act (CLIA), 416
 Cluster analysis, 47
 Cocaine dependence, genetic determinants of, 369–370
 Cohort studies, 53–55
 classification of, 54
 Cole, Toby B., xiv, 159
 Colon cancer, 143, 241
 genetic and environmental factor interactions in, 249–250
 risk factors and molecular pathways associated with, 244
 Community-based case–control study, 55–56
 Community health impact analysis, 402–404
 Comparative genomic analysis, 440
 Comparative genomic hybridization (CGH), for measuring gene dosage, 31–32
 Comparative genomics, 436
 Complex diseases, multiple environmental and genetic factors in, 70
 COMT polymorphisms, 145t, 146
 Concordance, 293–294
 Confounding factors
 controlling, 65
 in epidemiologic research, 64–67
 importance of, 66–67
 Consequence-based ethical analysis, 388
 Controls. *See also* Case–control studies
 in epidemiologic research, 60–62
 in population-based case–control studies, 67–69
 Copper malabsorption, 344–345. *See also* Cu²⁺-transporting ATPase; CuZnSOD gene
 Coreceptors, HIV infection and, 316–317
 Core commitments, 388
 Coronary artery disease, risk of, 277t
 Coronary heart disease (CHD), 271

- Costa, Lucio G., xiv, 1, 91, 159, 197, 213, 253, 377
- Cost–benefit analysis, 393
- Covicine, 347–348
- CpG methylation, 326. *See also*
Cytosine–guanine (CpG)
dinucleotides
- Crigler–Najjar syndromes, 132
- Cross-sectional studies, 58–59
- Cruciferous vegetables
cancer and, 349
lung cancer risk and, 229
- Cu²⁺-transporting ATPase, 344. *See also*
Copper malabsorption
- Culture, effects on health, 403
- CuZnSOD gene, 264, 265
- CVD etiology, 272. *See also*
Cardiovascular disease (CVD)
- CVD risk factors, 272
- CXCR4 receptor, 317
- Cycle sequencing technique, 18
- CYP1A1
expression of, 102
function of, 103–104
lung cancer survival and, 233–234
mutations of, 104–105
polymorphisms of, 57–58, 219–220
- CYP1A1 activity
induction of, 207
lung cancer and, 218–221
- CYP1A1 induction, molecular
mechanism of, 102
- CYP1A2
function of, 105
mutations of, 105–107
- CYP1A2 gene, multiple mutations
within coding regions of, 106
- CYP1A2 genotype–cancer association
studies, 106–107
- CYP1A2 polymorphism, drug toxicity
and, 105–106
- CYP1B1
function of, 107–108
mutations of, 107–108
- CYP1 family, 101
- CYP1 induction, 102
- CYP2A6
function of, 108
mutations of, 108–109
- CYP2A13, function and mutations of,
109
- CYP2C9 polymorphism, 113
- CYP2D6
lung cancer and, 221–222
nicotine/tobacco dependence and,
365–366
- CYP2D6 activity, lung cancer and,
219
- CYP2D6 polymorphism, 113
opioid dependence and, 368
- CYP2E1
function of, 109–110
genotypes of, 25
lung cancer and, 222–223
mutations of, 110–112
polymorphic alleles of, 223
- CYP2E1 activity, alcohol exposure and,
362–363
- CYP2 family, additional members of,
112–113
- CYP2J2, 118
- CYP3A
function of, 113–114
polymorphism of, 114
- CYP3A4, semisynthetic opioid
dependence and, 368
- CYP3A4/5 mutations, 114–115
- CYP3A5
genetic variants and altered
xenobiotic metabolism associated
with, 115–116
genetic variants and disease risk
associated with, 116–117
- CYP3A5 protein, 114–115
- CYP3A7, function and mutations of,
114
- CYP4A11, 118
- CYP4F2, 118
- CYP enzymes, 97
- CYP proteins, 97

- Cytochrome P450 2E1 enzyme, alcohol metabolism through, 362
- Cytochrome P450 enzymes (CYPs), 92.
See also CYP entries
- Cytochrome P450 polymorphisms, 95, 125–126
- Cytochrome P450 system, nicotine metabolism and, 355
- Cytochromes P450, 101–118. *See also* CYP entries
- gene–environment interactions of, 99–101
 - lung cancer and, 218–223
- Cytokines, celiac disease and, 331
- Cytosine–guanine (CpG) dinucleotides, 32–33. *See also* CpG methylation
- Cytosine methylation, 326
- DARC* gene, 311–312
- Data pooling, 70
- Daubert v. Merrell Dow Pharms., Inc.*, 425
- Deep intronic variants, 3
- Deep vein thrombosis (DVT), 280–281
- δ -opioid receptor gene, alcohol dependence and, 364
- Dementia, in Alzheimer's disease, 254
- Denaturation, in polymerase chain reaction, 20
- Deoxynucleotide triphosphates (dNTPs), 20
- De Roos, Anneclaire, xiv, 51
- Detoxifying enzyme, microsomal epoxide hydrolase as a, 174
- Developmental epigenetic determinants, of adult phenotype, 325–328
- Diabetes. *See also* Type 1 diabetes; Type 2 diabetes
- geographic/economic prevalence pattern of, 287t
 - prevalence of, 288, 289
- Diabetes mellitus, 286
- Diagnostic criteria, for neurodegenerative diseases, 267
- Dideoxynucleotide (ddNTP), 18
- Diergaarde, Brenda, xiv, 397
- Diet. *See also* Food entries
- colon and rectum cancer and, 244
 - esophageal cancer and, 243
 - role in colon cancer, 249–250
- Dietary adjustments, amino acid and protein metabolism disorders requiring, 332t
- Dietary antigen immune response, genetic differences in, 329–331
- Dietary carcinogens, genetic differences in metabolism of, 345–347
- Dietary compounds, hormonally active, 328
- Dietary isothiocyanates, GSTs and, 229
- Differential gene expression, statistical methods for identifying, 45–46
- Differential misclassification, 63
- Differential susceptibility, ethics and, 15
- 1,25- α Dihydroxycholecalciferol, 341
- Disease. *See also* Cancer; Diabetes; Diseases; Infectious disease(s); Neurodegenerative diseases; Occupational illness
- COMT activity in, 146
 - gene dosage and, 29
 - ion-channel-related, 209
 - linked to nonfunctional DNA repair systems, 193
 - PON1 polymorphisms associated with, 163–164
 - PON1 status and, 167
 - relative recurrence risk for, 78
- Disease pathogenesis, modeling along a continuum of, 304–305
- Disease phenotypes, 73–74
- Disease prevention, responsibility for, 393

- Disease risk(s)
 CYP2E1 polymorphisms and, 111
 effects of haplotypes on, 85
 GSTM1 deletion and, 152–153
 understanding, 15–16
- Disease risk cohort study, 54t
- Diseases. *See also* Alzheimer's disease (AD); Disease; Parkinson's disease (PD); Type 1 diabetes; Type 2 diabetes
 complex, 213
 infectious, 303–307
 neurodegenerative, 173, 253–269
- Disease susceptibility
 evolution of, 306
 mEH polymorphisms and, 177
 SNPs that increase, 190
- Divalent metal transporter (DMT-1), 343
- Dizygotic (DZ) twins, diabetes among, 293–294
- DNA. *See also* DNA damage; DNA repair
 base excision repair in, 182–185
 chemical instability of, 180
- DNA backbone, breaks in, 182
- DNA chip, 36
- DNA damage, 180–181
 bypass of, 192–193
 reducing, 195
 repair mechanisms for, 229–230
 reversal of, 181–182
- DNA glycosylases, 184
- DNA instrument technology, 18–19
- DNA methylation, 32–33
- DNA microarray analysis, 37
- DNA nucleotides, mispairing of, 187
- DNA polymerases, thermostable, 21
- DNA polymorphisms, 3
- DNA repair
 capacity for, 93
 diseases involving, 193
 lung cancer risk and, 229–231
- DNA repair enzymes, 179–196. *See also* DNA damage
 mutator phenotype and, 194–196
- DNA sequencer platform, automated, 26
- DNA sequencing, 17–19
- DNA strands, non-homologous end joining of, 189–190
- DNA strand segment, amplification of, 20
- DNA technologies, risk perception concerning, 449–450
- DNA variance/detection, 17–32
- Dopamine receptor genes, relationship to opioid dependence, 368
- Dopamine receptors, 356
- Dopamine-related proteins, relationship to tobacco dependence, 366
- Dopamine release, addiction and, 356
- Dopamine synthesis enzymes, nicotine dependence and, 367
- Dopamine transporter gene, role in alcohol dependence, 363–364
- Dopamine transporter gene polymorphisms, nicotine/tobacco dependence and, 366–367
- Dopamine transporters, cocaine dependence and, 370
- Dose–response assessment, 436
- Dose–response curve, 437f
- Double-strand break repair, 189–191
- Drug development, pharmacogenetics research and, 10
- Drug metabolism, PON1 and, 167–168
- Drug-metabolizing enzyme polymorphisms, 113
- Drug reactions
 genetically conditioned, 2
 relationship to enzyme variations, 1
- Drug-resistant mutants, 195
- Drugs
 access to, 392–393
 acetylation of, 139

- bimodal distribution of response of, 9
- for CVD risk factor levels, 278–279
- Drug sensitivity, polymorphism associated with, 169–170
- Duffy antigen, 311–312
- Dye flip experiment, 40

- Eaton, David L., xiv, 1, 91, 127, 213, 377
- Ecogenetic risk information, effects of exposure to, 408
- Ecogenetics, ix–x, 2, 11–12. *See also* Ecogenetic tools
 - applications of, 383, 384t
 - challenges in the study of, 250–251
 - ethical, legal, and social implication issues related to, 377, 381–395
 - historical perspectives on, 7–16
 - infectious disease, 303–319
 - key genetic polymorphisms relevant for, 5
 - nutritional, 13
 - origins of, 7–8
 - public health and clinical implications of, 15–16
 - role in toxic tort litigation, 423–425
 - social and psychological aspects of, 397–409
- Ecogenetics information, development and growth of, 450
- Ecogenetic studies, statistical issues in, 73–88
- Ecogenetic tools, 17–49
- Ecogenetic variation, classes of environmental agents with, 12t
- Edwards, Karen L., xiv, 285
- Effect measure modification, 279
- Electrical injury, role in amyotrophic lateral sclerosis, 264
- Employment discrimination, 421
- Endogenous cannabinoid system, 358
- Endogenous DNA damage, 180
- Endogenous opioid system, 357
- Environmental agents, ecogenetic variation of, 12t
- Environmental exposure(s)
 - familial influence on, 402
 - misclassification of, 63
 - type 2 diabetes and, 289–290
 - widely occurring, 55
- Environmental Exposure Technology Development committee, 441
- Environmental factors
 - gene mutation impact and, 126
 - multiple, 70
- Environmental Genome Project (EGP), 4–5, 14, 413, 444
- Environmental hazards, risk assessment of, 379. *See also* Environmental health risk assessment; Environmental risk factors
- Environmental health
 - areas of concern for, 383
 - genetics and, 381
 - risk management framework for, 447
- Environmental health risk assessment, 428. *See also* Environmental risk factors
- Environmental justice, 382–383
 - concept of, 378
- Environmental justice/equity movements, 403
- Environmental Protection Agency (EPA), 445–446
- Environmental response genes, 4–5, 14, 442
- Environmental risk factors. *See also* Environmental health risk assessment
 - for Alzheimer's disease, 256–257
 - for amyotrophic lateral sclerosis, 264–265
 - for Parkinson's disease, 260–262
- Environmental standards, tightening, 417
- Environmental susceptibility genes, 377, 378
- Environmental toxin metabolism, CYP3A5 and, 115

- Environmental toxins, BChE and, 172–173
- Enzyme-catalyzed metabolic reactions, 325
- Enzyme recognition sites, 27
- Enzyme variations, relationship to adverse drug reactions, 1. *See also* DNA repair enzymes
- Epidemiologic approaches, 51–71
framework for studying gene–environment interactions, 52–53
- Epidemiologic evaluation, 433–436
- Epidemiologic research. *See also* Epidemiologic studies
confounding factors in, 64–67
determining exposures in, 63–64
information bias in, 62–64
methodological considerations for, 59–69
selection bias in, 60–62
- Epidemiologic studies. *See also* Epidemiologic research;
Epidemiologic study designs
criteria for, 435
types of, 434
- Epidemiologic study designs, 53–59
case–control studies, 55–58
cohort studies, 53–55
cross-sectional studies, 58–59
- Epigenetic information, 32
- Epoxide hydrolases (EHs), 159, 173–177
background of, 173–174
mammalian, 176t
microsomal, 174–176
soluble, 174
substrates of, 175f
- trans*-Epoxides, metabolism of, 174
- Equal Employment Opportunity Commission (EEOC), 413, 421
- ER α gene, 204
polymorphisms in, 205
- ER β gene, 204
polymorphisms in, 205
- Erythrocyte invasion polymorphisms, 311–312
- Erythrocytic cycle, 308
- Escherichia coli*, mismatch repair in, 187, 188f
- Esophageal cancer(s), 239–240, 242–243
genetic and environmental factor interactions in, 245–247
- Esophageal squamous cell carcinoma, risk factors and molecular pathways associated with, 242–243
- Ester-containing drugs, BChE and, 173
- Estrogen oxidation, CYP3A5 and, 117
- Estrogen receptors, 204–205
- Ethical analysis, traditional approaches to, 388
- Ethical issues, 377
asthma case study and, 385–387
core concepts in, 382–383
ecogenetics-related, 378, 381–395
- Ethical, legal, and social implications (ELSI) issues, 377
- Ethics, differential susceptibility and, 15
- Etiologic heterogeneity, 267–268
- European Prospective Investigation into Cancer and Nutrition (EPIC), 55
- Exogenous DNA damage, 180
- Expectation–maximization (EM) algorithm, 84
- Experimental design, in microarray studies, 41–44
- Experimental studies, in cardiovascular disease, 276–278
- Exposed populations, epidemiologic evaluation of, 433–436
- Exposure assessment, 268, 440–442
personalizing, 441
- Exposure–disease paradigm, 441, 443
- Expressed sequence tags (ESTs), 37

- Factor misclassification, research validity and, 62–63
- Factor V Leiden, 274–275, 280–281
- Fair Employment and Housing Act (FEHA), 422
- Falciparum malaria, 308
resistance to, 312
- False discovery rate (FDR), 46
- False discovery rate methods, 87
- False-positive genes, controlling the number of, 45–46
- Familial AD, 257. *See also* Alzheimer's disease (AD)
- Familial adenomatous polyps (FAP), 244
- Familial health impact analysis, 401–402
- Familial PD, 262. *See also* Parkinson's disease (PD)
- Family-based controls, 67–68
- Family-based gene mapping methods, 79–83
- Family history, in type 2 diabetes, 298–299
- Family studies, of addiction, 353
- Farin, Frederico M., xiv, 17
- Fatty-acid-binding protein (FABP2), 338–339
- Faustman, Elaine M., xiv, 427
- Favism, 347–348
- Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), 444
- Federal Water and Pollution Control Act (FWPCA), 444
- Fenthion metabolism, 120
- Fetal liver, CYP3A7 in, 114
- Finland–United States Investigation of NIDDM Genetics (FUSION) study, 296
- Flavin-dependent monooxygenases (FMOs), 92. *See also* Flavin monooxygenases (FMOs); FMO entries
- Flavin monooxygenase genes, polymorphisms in, 95
- Flavin monooxygenases (FMOs), 97, 118–125. *See also* Flavin-dependent monooxygenases (FMOs); FMO entries
gene–environment interactions of, 99–101
polymorphisms among, 125–126
- Flavonoids, 349
- Fluorescent dyes, efficiency of, 40
- Fluorescently labeled targets, generating, 38–39
- Fluoride alleles, 171
- FMO1, 118–121. *See also* Flavin monooxygenases (FMOs)
function of, 118–120
mutations of, 120–121
- FMO1*6 mutation, 120–121
- FMO2, 124
- FMO3, 121–124
function of, 121
mutations of, 123–124
- FMO4, 124–125
- FMO5, 125
- FokI* polymorphism, 203, 204
- Folate, role in colon cancer prevention, 249
- Folate deficiency, 340
- Folate fortification, 407
- Food. *See also* Diet; Dietary entries;
Food preference
choices of, 321
as an environmental agent, 13
genetically engineered, 406
- Food allergy, 329–330
- Food and Drug Administration (FDA), 416
genomic data guidance document of, 445
- Foodborne carcinogens, 321–322
- Food preference, genetic differences in, 328–329
- Food proteins, 329–330
- Food Quality and Protection Act (FQPA), 439–440, 444
- Fryer-Edwards, Kelly, xiv, 381

- Functional polymorphisms, 3, 91, 92
- Furlong, Clement E., xiv, 159
- “Gain of function” mutations, 209
- Galactose-1-phosphate uridyl transferase (GALT) gene mutations, 336–337
- Galactosemia, 336–337
- γ -aminobutyric acid (GABA), alcohol dependence and, 364
- γ -aminobutyric acid system, 356–357
- Garrod, Archibald, 7–8
- Gastric cancer, 240–241. *See also* Gastrointestinal (GI) cancers; Stomach cancer
- genetic and environmental factor interactions in, 247–249
 - risk factors and molecular pathways associated with, 243
- Gastroesophageal reflux, esophageal adenocarcinomas and, 242–243
- Gastrointestinal (GI) cancers, 239–252
- genetic and environmental factor interactions in, 244–250
 - incidence of, 239–241
 - mortality related to, 242
 - risk factors and molecular pathways associated with, 242–244
- GC-RMA normalization, 45
- Geiss, Gary K., xiv, 159
- Gel-based genotyping assays, 28
- Gender differences. *See also* Sex differences
- in CYP1A1 function, 220–221
 - GST activity and, 227–228
- Gene amplification, 29–31
- Gene dosage
- comparative genomic hybridization for measuring, 31–32
 - RT-PCR method for measuring, 29–31
- Gene–environment (G \times H) interactions, 2
- alternative designs for evaluating, 299–300
 - in amyotrophic lateral sclerosis, 265
 - with ApoE, 258–259
 - disease-based approach to, 5–6
 - epidemiologic framework for studying, 52
 - in cardiovascular disease, 272–278
 - of P450s and FMOs, 99–101
 - in Parkinson’s disease, 263
 - textbook on, 5–6
 - in type 2 diabetes, 297–300
- Gene–environment interaction studies, control of confounding in, 65–66
- Gene expression, determining at the mRNA level, 34–49
- Gene expression investigations, data collection for, 70–71
- Gene expression profiling, 32
- applications of, 47–48
 - global, 36–49
 - principles underlying, 37
 - technology for, 48–49
- Gene–gene–environment interaction, 214
- Gene–gene interactions, in Parkinson’s disease, 263
- Gene heterogeneity, 268
- Gene mapping
- family-based methods in, 79–83
 - population-based methods in, 83–86
- Genes
- analyzing large numbers of, 14
 - response to environmental exposure, ix
- Gene therapy, 196
- Genetic aberrations, detecting and mapping, 32
- Genetically engineered food, 406
- Genetic biomarkers of exposure, in toxic tort litigation, 424
- Genetic determinants
- of addiction, 351–373
 - of alcohol dependence, 359–365
 - of cannabis use, 370–371
 - of cocaine dependence, 369–370

- of nicotine/tobacco dependence, 365–367
- of opioid dependence, 367–369
- Genetic differences
 - in amino acid and protein metabolism, 331–334
 - in carbohydrate metabolism, 334–337
 - in food preference, 328–329
 - in immune response to dietary antigens, 329–331
 - in lipid metabolism, 337–340
 - in metabolism of dietary carcinogens, 345–347
 - in mineral handling, 342–345
 - phytochemicals and, 347–349
 - in vitamin metabolism, 340–342
- Genetic discrimination, 422
- Genetic environmental interaction, in gastrointestinal cancers, 244–250
- Genetic epidemiology, of addiction, 353–354
- Genetic epidemiology studies, 434
 - haplotypes in, 201
- “Genetic exceptionalism,” 16
- Genetic factors, multiple, 70. *See also* Genetic risk factors
- Genetic heterogeneity, 74
- Genetic influences, type 2 diabetes and, 291
- Genetic information. *See also* Genetic knowledge
 - feedback of, 400
 - studies that utilize, 87
 - uniqueness of, 16
- Genetic knowledge, ethical issues related to, 383
- Genetic polymorphisms, 3–4
 - affecting receptors and ion channels, 197, 198
 - effect on lung cancer risk, 236–237
 - identifying, 4
 - in neurotransmitter and hormone receptors, 93
- Genetic predisposition
 - to food allergies, 330
 - “loaded gun” metaphor for, 442
- Genetic risk
 - familial influence on, 402
 - transmittal through family members, 401
- Genetic risk factors, interaction with social system, 398
- Genetic risk information, 401–402
 - reaction to, 400
- Genetics
 - basic concepts in, 74–77
 - molecular developments in, 14–15
- Genetic screening tests
 - predictive, 405
 - workplace, 418–419
- Genetic susceptibility, 4
 - environmental hazard risk assessment and, 379
- Genetic susceptibility testing, 411–413. *See also* Genetic testing
 - incentives to apply, 418–420
 - legal issues related to, 413–417
 - limits on, 420–423
 - in the workplace, 417–423
- Genetic technologies, animal bioassays and, 432–433
- Genetic test commercialization, legal issues related to, 415–416
- Genetic testing, 87. *See also* Genetic susceptibility testing
 - by federal employers, 422
 - implications of, 377
 - justifying, 385
 - stakeholders in, 390–391
 - surreptitious, 421
 - in the workplace, 385, 404–405
- Genome, linkage disequilibrium and haplotype blocks in, 281–282
- Genomewide significance, 81
- Genomic regions, determining methylation of, 32–34
- Genomic revolution, 428
- Genomics research, asthma-related, 386–387

- Genomic technologies
 growth of, 431–432
 legal issues related to, 411–426
- Genomic variation, extent of, 282
- Genotyping
 high-throughput, 251
 TaqMan-based, 28–29
- Gerbich-negative (Ge^-) phenotype, 312
- Gilbert syndrome, 132
- Global gene expression profiling, 36–49
- Global nucleotide excision repair, 185
- Glucose-6-phosphate dehydrogenase (G6PD), 347–348
- Glucose homeostasis, 285
- Glucuronidation, 128, 129
- Glutamate receptors, 357
- Glutathione conjugation, 147f
- Glutathione *S*-transferases (GSTs), 24–25, 146–154, 325, 348–349.
 See also GST entries; GSTM entries; GSTP entries; GSTT1 entries
 dietary isothiocyanates and, 229
 lung cancer and, 226–229
 soluble, 147–148
 tissue distribution and substrates of, 149–150t
- Gluten-sensitive enteropathy, 330–331
- Glycophorin C, 312
- Goodness-of-fit chi-square test, 75
- G-protein-coupled receptors, 198
- G-protein-linked receptors, 197
- GSTM1. *See also* Glutathione *S*-transferases (GSTs)
 lung cancer and, 226–228
 lung cancer survival and, 233–234
 polymorphism of, 152–153
- GSTM1/CYP1A1 enzyme
 combination, 232
- GSTM3 polymorphism, 148
- GST-mediated reactions, 147
- GSTP1, 147
 lung cancer and, 228
 polymorphisms of, 148–150
- GSTP1 variants, influence on lung cancer risk, 235
- GSTP1313GG polymorphism, 153
- GST polymorphisms, 148, 151–152t, 349
- GSTT1, lung cancer and, 228
- GSTT1 enzyme, 443–444
- Haldane, J. B. S., 8, 309–311
- Hampson, Lindsay A., xiv, 381
- Haplotype(s), 76
 in genetic epidemiology studies, 201
- Haplotype blocks, 281–282
- Haplotype frequency estimates, 84–85
- HapMap project, 281
- Hardy–Weinberg disequilibrium (HWD), 75
- Hardy–Weinberg equilibrium (HWE), 74–75
- Hazard identification, 430–436
 animal bioassays in, 432
- Hazardous sites, distribution of, 403–404
- Head injury, Alzheimer’s disease and, 258
- Health, biopsychosocial determinants of, 398, 399t
- Health-based standards, 446
- Healthcare resources, allocation of, 392
- Health choices, guidance on, 400
- Health disparities, reasons for, 403
- Health impact analysis
 community, 402–404
 familial, 401–402
 individual, 398–401
 levels of of, 398–407
 organizational, 404–405
 political, 406–407
 residential, 405–406
 sociocultural, 402–404
- Health Insurance Portability and Accountability Act of 1996 (HIPAA), 16
- Health issues, justice in, 393–394
- Health promoting behaviors, stress and, 400

- Health-related norms, familial, 401
- Health resources, local, 405–406
- Health risks, surrounding variables and, 398
- Heart attack, 271. *See also*
Cardiovascular disease (CVD)
- Helicobacter pylori*
gastric cancer and, 243
role in stomach cancer, 247–249
- Hemochromatosis, 343–344
- Hemoglobin, sickle cell, 309–311
- Hemoglobinopathies, 309–311
- Hemolytic anemia, 8–9
- Hepatocellular carcinoma, 115
- Hepatocyte nuclear factor 4a
(HNF-4 α , HNF-4alpha), type 2 diabetes and, 296
- Hereditary nonpolyposis colorectal cancer syndrome (HNPCC), 244
- Heredity, interplay with environment, ix
- Heritability estimates, 294
- Heroin dependence, 367–368
- Heterocyclic amines (HA), 345–346
- HFE molecule, 343–344
- High-density lipoproteins (HDLs), 337
- High-density SNP arrays, 29
- HIV pathogenesis, 315. *See also*
Human immunodeficiency virus (HIV)
- HNF-1alpha mutations, 293
- Homologous recombination, 190, 191f
- Hormonally active dietary compounds, predisposition for biochemical insult and, 328
- Hospitalized controls, 61
- Host–pathogen coevolution, 305–306
- Host–pathogen interactions, animal models of, 306–307
- Host response, to HIV, 315
- Host susceptibility, to infectious disease, 304
- Host susceptibility/resistance loci, 318
- Hot-start PCR, 21–23
- Human Cytochrome P450 (CYP)
Allele Nomenclature Committee, 97
- Human Genome Project, 14
- Human immunodeficiency virus (HIV), 314
genes implicated in resistance or susceptibility to, 317t
host response to, 315
pathogenesis of, 318
- Human leukocyte antigen (HLA)
complex, 330–331
- Humans, mismatch repair in, 188–189
- Human somatic cells, mutation rate for, 194
- Human studies, genetic data in, 86–87
- Human variability, risk assessment and, 427–430
- Hybridization
process of, 37
RNA, 38–39
- Hydrolytic enzymes, 159
- Hyperbilirubinemia, 132
- Hyperglycemia, 286
- Hyperhomocysteinemia, 340–341
- Hyperphenylalaninemia, 333
- Hypoglycemia, sulfonylureas and, 291–293
- Identical by descent (IBD) alleles, 81–82
- Inborn errors of metabolism, 7, 13
- Individual health impact analysis, 398–401
- Individuality, genetically determined, 8
- Infectious disease(s)
global incidence of, 307t
host susceptibility to, 304
modeling susceptibility to, 304–307
modern view of, 303–304
- Infectious disease ecogenetics, 303–319
malaria, 307–313
- Information bias, in epidemiologic research, 62–64

- Institutional review boards (IRBs), 414, 415
- “Insulin-dependent” diabetes mellitus (IDDM), 286
- Interindividual variability, genetic basis of, 96–99
- Intestinal fatty-acid-binding protein (FABP2), 338–339
- Intracellular receptors, 197
- Investigators, exchange of information and expertise among, 251–252
- In vitro assays, 433
- Ion channels, 198
 - clinical significance of, 210t
- Iron, excessive intake of, 343–344
- Isoflavonoids, 349
- Isoleucine, 333
- Isothiocyanates (ITC), 348
 - dietary, 229
- Isozymes, 325
- Japanese populations, lung cancer in, 220, 230
- Johnson Controls* decision, 419
- Justice, in health issues, 393–394
- “Juvenile-onset” diabetes mellitus, 286
- Kelada, Samir N., xiv, 253
- Kidney tumors, 156
- Knockout mice, 14
- Ku proteins, 189, 190
- LACOMT gene, 145–146
- Lactase persistence, 334–336
- Lactase phlorizin hydrolase (LPH), 334–336
- Lampe, Johanna W., xiv, 321
- Latent risk damage claims, 423–424
- L-DOPA, 260
- Lead, pharmacokinetics of, 203–204
- Legal issues
 - in genetic susceptibility testing, 378–379
 - genomic-technology, 411–426
 - related to susceptibility testing, 413–417
- Leucine, 334
- Lewy bodies, 259
- Likelihood models, 78–79
- Likelihood ratio tests, 75, 79–80, 85
- Linkage, 76
- Linkage analysis, 79–83
- Linkage disequilibrium (LD), 281–282
- Linkage disequilibrium coefficient, 76
- Linkage studies
 - issues that affect, 82–83
 - of type 2 diabetes, 294–295
- Lipid levels, changes in, 277–278
- Lipid metabolism, genetic differences in, 337–340
- Lipoprotein lipase (LPL), 337
- Lipoprotein metabolism, 338–340
- Literature reviews, 70
- Liver disease, alcoholic, 111–112
- Locus heterogeneity, 268
- LOD score, 80, 81
- Loeb, Lawrence A., xv, 179
- “Long-patch repair,” 183, 184–185
- Loss-of-function defects, 209
- Lou Gehrig’s disease, 253. *See also* Amyotrophic lateral sclerosis (ALS)
- Low-density lipoprotein (LDL), 337
- Low-density lipoprotein receptor (LDLR), 272
- Lowest observable effect levels (LOAELs), 436–438, 440
- Lung adenocarcinoma, 109
- Lung cancer, 104, 109, 215–238
 - biotransformation enzyme combinations and, 231–233
 - biotransformation enzyme polymorphisms and, 218–229
 - classes of carcinogens important in, 216–218
 - CYP2E1 and, 111
 - cytochrome P450s and, 218–223
 - diet and, 229
 - future research in, 234–238

- genetic contributions to, 216
- GSTM1 polymorphism and, 153
- mEH polymorphisms and, 177
- tobacco use and, 215–218
- Lung cancer histologies, development of, 235
- Lung cancer location, influence of genotype on, 232
- Lung cancer risk
 - DNA repair and, 229–231
 - effect of genetic polymorphisms on, 236–237t
- Lung cancer survival, role of polymorphisms in, 233–234
- Lymphocytes, DNA adduct formation in, 105
- m1/2* alleles, 220
- Macrominerals, 342
- Major histocompatibility complex (MHC), 318
- Malaria, 306, 307–313
 - epidemiology, life history, and pathology of, 307–309
 - erythrocyte invasion polymorphisms and, 311–312
 - genetic traits affecting susceptibility to, 308
 - hemoglobinopathies and, 309–311
 - host susceptibility/resistance to, 309–311
 - resistance to, 313
 - susceptibility to, 313
 - thalassemias and, 311
- Malaria severity polymorphisms, 312–313
- Maldigestion, sucrose, 336
- Malignant hyperthermia, 10
- Malignant phenotype, multiple factors associated with, 245
- Mammalian epoxide hydrolase, classes of, 176t
- Mammalian sodium channel subunits, 208t
- Maple syrup urine disease (MSUD), 333–334
- Marijuana, 358
- Marker phenotype, 83–84
- Markers, association with traits, 83
- Markov chain Monte Carlo (MCMC) methods, 87
- Mastroianni, Anna, xv, 411
- Matrix-based CGH, 32
- Matrix metalloproteinase-3 gene, 273
- Maturity-onset diabetes of the young (MODY), 286, 291. *See also* MODY3
 - genetic mutations responsible for, 292t
- Meat intake, cancer and, 345–346
- Medical information, sensitivity of, 16
- Medical Research Council Human Genetics Unit, 97
- MegaBACE 1000 capillary-array-based platform, 19
- Melanoma, 401
- Membrane-bound GSTs, 147
- Membrane-bound STs, 133
- Mendel's second law, 76
- Menke's disease, 342, 344–345
- Messenger RNA (mRNA), gene expression at the level of, 34–49
- Metabolic disorders, 7–8
- Metabolism
 - amino acid and protein, 331–334
 - carbohydrate, 334–337
 - of dietary carcinogens, 345–347
 - lipid, 337–340
 - lipoprotein, 338–340
 - of phytochemicals, 348–349
 - vitamin, 340–342
- Metals
 - role in Alzheimer's disease, 256–257
 - role in amyotrophic lateral sclerosis, 264–265
 - role in Parkinson's disease, 263
- Metadone, 368

- Methylation, 143–144
 of specific genomic regions, 32–34
 tissue-specific, 326–328
- Methylation-specific PCR, 33
- Methylenetetrahydrofolate reductase (*MTHFR*), 249–250, 340–341
- Methylmercury (MeHg) exposure, 439
- Methyltransferases, 143–146
- Microarray data, processing and analysis of, 44–47
- Microarray experiments, randomization in, 42–43
- Microarrays, high-throughput capacity of, 87
- Microarray studies, experimental design considerations in, 41–44
- Microarray technology, toxicology and, 48
- Microminerals, 342
- Microsatellites, 26
- Microsomal epoxide hydrolases (mEHs), 174–176
 lung cancer and, 225–226
 polymorphisms in, 177
 substrates of, 176t
- Mineral handling, genetic differences in, 342–345
- Mismatched (MM) oligonucleotide probes, 41
- Mismatch repair, 187–189
- Mismatch repair proteins (MMRs), 187
- “Model-based” linkage analyses, 81
- Modeling, of susceptibility to infectious disease, 304–307
- Modifying factors (MF), 439
- MODY3, pharmacogenomic effects in, 291–293. *See also* Maturity-onset diabetes of the young (MODY)
- Molecular determinants, of nutrient-dependent phenotypes, 323–328
- Molecular developments, modern, 14–15
- Molecular fingerprints, 14
- Molecular signatures, 432
- Monks, Stephanie A., xv, 73
- Monoamine oxidase A and B, 260
- Monoamine oxidase B (MAOB), 262
- Monogenic diseases, 322
- Monosodium glutamate (MSG), 329
- Monozygotic (MZ) twins, diabetes among, 293–294
- Morphine dependence, 367–368
- Motulsky, Arno G., xv, 2, 7, 11
- mRNA level measurement, aspects of cDNA arrays affecting, 39–40
- mRNA levels, TagMan-based quantitation of, 35–36
- MspI* restriction enzyme, 27–28
- Mullis, Kary, 20
- Multilocus genotype, 83–84
- Multiple testing, 87–88
- Multiplex PCR, 24–25
- Multiplicative interaction models, 279–281
- μ -opioid receptor gene
 alcohol dependence and, 364
 cocaine dependence and, 370
- Mutation rate, for human somatic cells, 194
- Mutations
 BChE, 170–172
 DNA damage leading to, 180–181
 in gene regulatory regions, 3
 xenobiotic metabolism and, 97–99
- Mutator phenotype, 194–196
 cancer treatment/prevention and, 195
- mutL homologs (MLHs), 188–189
- mutS homologs, 188
- Mycotoxins, 346
- Myeloperoxidase (MPO), 223–224
- Myotonic disorders, 209
- Myxoma virus, 306
- N*-acetyltransferases (NATs), 139–143.
See also NAT entries
 relationship to cancer, 224–225
 tissue distribution and substrates of, 140t

- NAD(P)H quinone reductases, gene loci that code for, 155. *See also* NQO entries
- NAT1, 225. *See also* N-acetyltransferases (NATs) polymorphisms of, 139–141
- NAT2, 224–225
polymorphisms of, 141–143
- NAT conjugation reaction, 140f
- NAT genes, 139
- National Institute for Occupational Safety and Health (NIOSH), 413, 414
- National Institutes of Health
“certificate of confidentiality,” 415
- NAT polymorphisms, 139–143
- Nazar-Stewart, Valle, xv, 215
- Neighborhood health impact analysis, 405–406
- Nested case–control study, 56
- Neural tube defects, 407
- Neuritic plaques, 254, 255f
- Neurodegenerative diseases, 253–269
Alzheimer’s disease, 254–259
common themes among, 265–267
environmental risk factors in, 256–257
familial forms of, 266
issues related to, 267–269
Parkinson’s disease, 259–263
role of BChE in, 173
study strategies for, 269
- Neurofibrillary tangles (NFTs), 254, 255f
- Neurotransmitter systems, substance dependence and, 356–357
- Nicotine dependence, studies of potential genetic determinants of, 361t. *See also* Cigarette entries; Nicotine/tobacco dependence; Smoking entries; Tobacco entries
- Nicotine elimination, 108
- Nicotine/tobacco dependence, genetic determinants of, 365–367
- Nicotinic cholinergic receptors, 358
- Nicotinic receptors, 367
- NIDDM1 gene, 296
- NIEHS National Toxicology Program, 433
- Nifedipine response element (NFSE) mutation, 117
- Nitrosamines, procarcinogenic, 109
- Nondifferential misclassification, 62
- Nonfunctional DNA repair systems, diseases linked to, 193
- Nonhomologous end joining (NHEJ), 189–190
- “Non-insulin-dependent” diabetes mellitus (NIDDM), 286. *See also* NIDDM1 gene
- Nonspecific cholinesterase, 169
- Nonsynonymous mutation, 98
- Nonthreshold dose response, 436
- No observable effect levels (NOAELs), 436–438, 440
- Normalization process, 44–45
- Norman Bloodsaw v. Lawrence Berkeley Laboratory*, 420
- Northern blot analysis, 35
- NQO (NAD[P]H:quinone oxidoreductase), tissue distribution and substrates of, 155t. *See also* NAD(P)H quinone reductases
polymorphisms of, 157
- NQO1, 154–156
polymorphic variants of, 156
- NQO2, 154–155
- Nucleotide excision repair (NER), 185–186, 231
- Nucleus accumbens area, 356
- Nurses Health Study, 54–55
- Nutrient-dependent phenotypes, molecular determinants of, 323–328
- Nutrient exposures, neonatal, 325–326
- Nutrient metabolism, 325

- Nutrients, 321, 322t
- Nutrition, biologic mechanisms
underpinning adaptations to,
326
- Nutritional ecogenetics, 13
- Occupational illness, 417–418
liability for, 419
- Occupational Safety and Health Act of
1970 (OSHA), 13, 418
- OGG1 gene, lung cancer and, 230
- OGG1 glycosylase, 184
- Oligonucleotide arrays, 41
- Oligonucleotide-based microarray
techniques, 34
- Omega-3 fatty acids, 339
- Omenn, Gilbert S., xv, 7, 427
- Omenn Commission, 447
- One-color (one-channel)
oligonucleotide arrays, 41
- Online Mendelian Inheritance in Man*
(OMIM), 73
- Open-source software programs, 47
- Opioid dependence, genetic
determinants of, 367–369
- Opioid receptor genes, relationship to
opioid dependence, 369
- Opioid receptors, 357
- Opioids, semisynthetic, 368
- Organizational health impact analysis,
404–405
- Organophosphorus compounds, PON1
status and, 166–167
- Organophosphorus insecticides, 161
- Ovalocytosis, 312
- Oxidized lipids, metabolism of, 161
- p16 gene, 242
- p53 gene, 242
- P450 enzyme induction, 100
- P450 enzymes, additional, 117–118
- PAINT software tool, 46–47
- Paraoxonase (PON1), 159, 160–168.
See also PON1 entries
background of, 160–161
catalytic efficiencies of, 166–167
drug metabolism and, 167–168
genotyping and disease in, 163–164
promoter region polymorphisms in,
163
- Paraoxonase activity, polymorphic
distribution of, 161–163
- Parasitemias, 308
- PARK* genes, 262, 267
- Parkinson's disease (PD), 71, 253,
259–263. *See also* Familial PD;
Sporadic PD
candidate genes related to, 262–263
environmental risk factors for,
260–262
gene–environment and gene–gene
interactions in, 263
pathogenesis of, 259–260
- Patient privacy issues, 16
- PCB (polychlorinated biphenyl)
exposure, 57–58
- PCR-based analyses, of tandemly
repeated sequences, 25–26. *See
also* Polymerase chain reaction
(PCR)
- PCR infidelity, 23
- PCR primers, design of, 33
- PCR products, analysis of, 23
- PCR-RFLP (restriction fragment
length polymorphism) method,
26–28
- PCR specificity, 21
- PCR yield, 23
- “Perceived risk,” 447–450
- Perfectly matched (PM)
oligonucleotide probes, 41
- Permutation distribution, 86
- Pesticide exposure, 402
- Pesticides
BChE mutations and, 172
role in Parkinson's disease, 260–261
- Pharmacogenetic research, priority and
standards in, 11
- Pharmacogenetics, ix, 2, 8–11
cautionary views about, 11

- Pharmacogenetics Research Network, 10
- Pharmacogenetic testing, 412
- Pharmacogenetic traits, rare, 9–10
- Pharmacogenomic effects, in *MODY3*, 291–293
- Pharmacogenomics
in cardiovascular disease, 278–279
commercial incentives as a factor in, 392
genomics research and, 386, 387
- Pharmacogenomics research, 392
- Pharmacogenomics Working Group, 10
- Pharmacokinetics, 93
- Pharmacologic substance dependence treatments, targeting, 372
- Phase I biotransformation enzymes, 92, 127
- Phase II biotransformation enzymes, 93, 127–128
- Phase III biotransformation reactions, 127
- Phenotype
developmental epigenetic determinants of, 325–328
differences in, 323
- Phenotypic variation
genes identified for, 73
technology related to, 74
- Phenylalanine hydroxylase (PAH)
activity, impaired, 333
- Phenylketonurias, 333
- Phenylthiocarbamide (PTC), 329
- PhIP conjugates, 106
- Photolyases, 181
- Photoreactivation, 181
- Phytochemicals, 321
genetic differences and, 347–349
metabolism of, 348–349
- Plasminogen activator inhibitor type 1
gene, 273
- Plasmodium*, 307
pathogenesis of, 318
- Policies, organizational, 404
- Polycyning, key stakeholders and, 391–392
- Political health impact analysis, 406–407
- Poly(A) polymorphisms, 202–203
- Polychlorinated biphenyls (PCBs), 431
- Polycyclic aromatic hydrocarbons (PAHs), 216–218
CYP1A1 and, 219
- Polymerase chain reaction (PCR), 24.
See also PCR entries
allele-specific, 25
efficiency of, 21
multiplex, 24–25
steps of, 22t
- Polymorphic genes, nutrient requirements and, 349–350
- Polymorphic receptors, clinical significance of, 210t
- Polymorphisms
functional implications of, 5
genetic, 3–4
risks associated with, 443–444
in xenobiotic conjugation, 127–158
- Polymorphism studies, hospital-based controls in, 227
- PON1* gene, 163f
- PON1* genetic variability, relationship to disease risk, 164–165
- PON1* levels, variability of, 165–166
- PON1* polymorphisms, 161–163
- PON1* status
determination of, 164–165
disease and, 167
organophosphorus compounds and, 166–167
- Population-based case–control studies, 59
choice of controls in, 67–69
- Population-based gene mapping
methods, 83–86
- Population-based genetic epidemiologic studies, 5
- Population-based health issues, justice in, 393–394

- Population-based studies, for lung cancer, 238
- Population stratification, 66
- Positive false discovery rate (pFDR), 46
- Poste, George, 10
- Potter, John D., xv, 321
- Potter's bronchitis, 11
- "Predict-and-prevent medicine," 10
- Predictive genetic testing, 412
- Principle-based ethical analysis, 388
- Privately funded research, 414
- Proinflammatory polymorphisms, gastric cancer and, 248–249
- 6-*n*-Propylthiouracil (PROP), 329
- Prospective cohort study, 54–55, 69
- Prospective studies, in cardiovascular disease, 275–276
- Prostate cancer, 117
- Protein aggregation, in neurodegenerative diseases, 265–266
- Protein metabolism, genetic differences in, 331–334
- Protein metabolism disorders, dietary adjustments for, 332t
- Proteins, in homologous recombination, 190
- Proteomics, 15
- Pseudocholinesterase, 9, 169
- Pst*I endonuclease, 27
- Public health
 - genetic susceptibility and, 391
 - implications of ecogenetics for, 15–16
 - issues in, 213–214
- Publicly funded research, 414
- Public policy, ecogenetic information and, 447
- Puget Sound Partners for Global Health Request for Pilot Projects, 409
- p* value, estimating, 86
- Q192R genotype, 164, 166
- Quantification software, 44
- Quantitative trait locus (QTL), 82
- Questionnaires, as a source of exposure information, 64
- Racial populations, allele frequency distributions among, 74
- Randomization principle, 42–43
- Raphe nuclei, 358
- Reactive oxygen species (ROS), 218, 256, 261
 - DNA damage caused by, 230
- Receptors, 197–198
 - adrenergic, 198–201
 - aryl hydrocarbon, 205–207
 - estrogen, 204–205
 - vitamin D, 201–204
- Recombinational bypass mechanism, 192
- Recombination fraction, 76
- Rectal cancer, 241
 - risk factors and molecular pathways associated with, 244
- Reference dose (RfD), 436, 439–440
- Relative recurrence risk, 78
- Relative risk (RR), 214, 280–281
- Relative risk ratio, 77
- Repair mechanisms, cellular, 181–193
- Replication, types of, 43–44
- Research, federal protections related to, 415
- Research approaches, to gene–environment interactions in CVD, 273–278
- Research data, adverse consequences of, 415
- Research proposals, review of, 415
- Research-related legal issues, 413–415
- Research validity, factor
 - misclassification and, 62–63
- Residential health impact analysis, 405–406
- Restriction endonucleases, 26
- Restriction enzymes, 27t
- Restriction fragment length polymorphism (RFLP), 26, 110

- Retrospective cohort study, 54–55
- Rettie, Allan E., xv, 95
- Risk, characterization of, 430, 436–444
- Risk assessment, 427–450
- of environmental hazards, 379
 - hazard identification in, 430–436
 - key objectives of, 430
 - use of, 428
 - variation in susceptibility and, 13
- Risk assessment framework, 428–430
- Risk Assessment in the Federal Government: Managing the Process* (red book), 428
- Risk factors, misclassification of, 63
- Risk information, individual reactions to, 400
- Risk management, 430, 444–450
- framework for, 447, 448f
- RNA processing/hybridization, 38–39
- Robust Multichip Average (RMA), 45
- Rodent malarias, study of, 313
- RT-PCR method, for measuring gene dosage, 29–31
- Rule-based ethical analysis, 388
- Sample sizes, in epidemiologic studies, 70
- Sanger method, of DNA sequencing, 18
- Saxon, Andrew J., xv, 351
- Scanner images, preprocessing of, 44
- Scarlet fever, 306
- Schwartz, Steven M., xv, 271
- Scientific evidence, in toxic tort litigation, 425
- “Screening study,” in cardiovascular disease, 273
- SDF-1 chemokine, 317
- Segregation studies, 77–79
- Selection bias, in epidemiologic research, 60–62
- Sense primer, 20
- Sensitivity analyses, 61
- Serotonin, 358–359
- Serotonin function, alcohol consumption/dependence and, 364–365
- Serotonin-related genes, cocaine dependence and, 370
- Serotonin transporter gene, polymorphism smoking and, 367
- Serotonin transporters, cocaine dependence and, 370
- Sex differences, in cardiovascular disease, 273–274. *See also* Gender differences
- Sherman, David R., xv, 303
- “Short-patch repair” process, 183–184
- Short tandem repeats (STRs), 26
- Sibling controls, 67–68
- Sibling pairs, sampling, 81
- Sickle cell anemia, 309
- Signaling molecules, 197
- Silent BChE mutations, 170–171
- Single-nucleotide polymorphism (SNP) genotyping, 28
- Single-nucleotide polymorphisms (SNPs), 1, 17, 323–325. *See also* SNP entries
- CYP1A1, 104
 - disease susceptibility increase via, 190
 - functional, 3
- SLC6A3–9 allele, smoking and, 366–367
- Slot blot analysis, 35
- Slowly developing diseases, investigating, 58–59
- Smith, Helen E., xv, 127
- Smoking. *See also* Cigarette entries; Nicotine entries; Tobacco entries
- alcohol pharmacokinetics and, 363
 - Alzheimer’s disease and, 258
 - Parkinson’s disease and, 261–262, 263
 - risk feedback related to, 400–401
 - role in cardiovascular disease, 274
 - twin studies on, 354

- Smoking behavior, CYP2A6 genotype and, 108
- Smoking–gene interactions, importance of, 274–275
- Smoking-related cancer, GSTM1 polymorphism and, 153
- SNP chips, 29. *See also* Single-nucleotide polymorphisms (SNPs)
- SNP Consortium, 444
- “Social capital,” 403
- Social Issues Committee of the American Society of Human Genetics (SISASHG), 16
- Sociocultural health impact analysis, 402–404
- SOD1* mutations, 267
- Sodium channel isoforms, 207–208
- Sodium channels, 207–209
- Software
- biological interpretation, 46
 - quantification, 44
- Soluble epoxide hydrolase (sEH), 174
- Solvent exposure, role in Alzheimer’s disease, 257
- Source population, 60
- Southeast Asian ovalocytosis (SAO), 312
- Southern blotting, 23–24
- Specific cholinesterase, 169
- Sporadic AD, 257–258. *See also* Alzheimer’s disease (AD)
- Sporadic complex diseases, 51
- Sporadic PD, 262. *See also* Parkinson’s disease (PD)
- Spouse controls, 67
- Squamous cell carcinoma, 56, 240
- Squamous cell lung carcinoma, 214
- Stakeholders
- policy decisions and, 391
 - in risk management, 447
- STAT6 gene, 330
- Statistical genetics studies, deviations from Mendel’s second law and, 76
- Statistical issues
- aggregation and segregation studies, 77–79
 - in ecogenetic studies, 73–88
 - family-based methods in gene mapping, 79–83
 - population-based methods in gene mapping, 83–86
- Statistical measures, in aggregation studies, 77–78
- Statistical methods, for identifying differential gene expression, 45–46
- Statistics, basic concepts in, 74–77
- ST-mediated conjugation reaction, 133. *See also* Sulfotransferases (STs)
- Stomach cancer, 143, 240–241, 242. *See also* Gastrointestinal (GI) cancers
- genetic and environmental factor interactions in, 247–249
 - risk factors and molecular pathways associated with, 243
- Stress, health promoting behaviors and, 400
- Stromelysin-1 gene, 273
- Structure–activity relationships (SARs), 431–432
- Student’s *t* tests, 45
- Study participation rates, 61–62
- Subpopulations, drugs targeted to, 10
- Substance dependence
- development of, 355
 - genetic risk for, 371
 - polygenic etiology of, 371
 - studies of potential genetic determinants of, 362t
- Succinylcholine sensitivity, 9–10
- Sucrase–isomaltase (SI), 336
- Sucrose maldigestion, 336
- “Suicide enzymes,” 182
- Sulfonation reactions, 132–133
- Sulfonyleureas, MODY3 and, 291–293

- Sulfotransferases (STs), 132–139. *See also* ST-mediated conjugation reaction; SULT entries
importance of, 133
tissue distribution and substrates of, 134–135t
- Sulindac sulfide (SID), 120
- SULT1A3, 136. *See also* Sulfotransferases (STs)
- SULT polymorphisms, 136–139
- SULTs (soluble STs), 133–139
- Susceptibility
assessment of, 442–444
multiple genes contributing to, 435
variation in, 11, 13
- Susceptibility genes, 322–323
for type 2 diabetes, 291, 294–295
- Susceptibility testing, 411–413
legal issues related to, 413–417
scientific considerations for, 412–413
- Susceptible populations, understanding, 450
- Sutton v. United Airlines Inc.*, 421
- Synonymous mutation, 98
- Synonymous variants, 3
- T2R bitter-taste receptors, 328
- “Take-home exposure,” 402
- Tandemly repeated sequences, PCR-based analyses of, 25–26
- Taq1 A gene, nicotine/tobacco dependence and, 366
- Taq1 A polymorphisms
alcohol dependence and, 363–364
cocaine dependence and, 370
- TaqMan-based allelic discrimination assay, 30f
- TaqMan-based genotyping, 28–29
- TaqMan-based quantitation, of mRNA levels, 35–36
- TaqMan probes, 28–29
- Targets, fluorescently labeled, 38–39
- Taste preference, genetic differences in, 321
- Tau gene, in neurodegenerative diseases, 265–266
- Tau protein, 256
- TCDD (2,3,7,8-tetrachlorodibenzo-*p*-dioxin), AhR activation and, 206
- Technical replication, 43
- Template switching, 192
- Tertiary amine substrates, FMO3 and, 121
- Test statistic, calculation of, 45
- Tetrachlorodibenzo-*p*-dioxin (TCDD) exposure, type 2 diabetes and, 289, 290
- Tetrahydrofolate, 340
- Tetrodotoxin (TTX) sensitivity, 208
- Thalassemias, 311
- Three Mile Island (TMI) litigation, 424–425
- Threshold-based dose response, 436
- Thrifty gene hypothesis, 297–298
- Thummel, Kenneth E., xv, 95
- Tiered testing strategies, 433
- Tissue transglutaminase (tTG), 331
- Tobacco, lung cancer and, 215–218. *See also* Cigarette entries; Nicotine entries; Smoking entries
- Tobacco carcinogens, 216
- Tobacco metabolism, complexity of, 234–235
- Tobacco-related cancers, 109
- Tobacco-specific *N*-nitrosamines (TSNA), 216–218
- ToxChip, 14–15
- Toxic action, mechanism of, 440
- Toxic exposure standards, 418
- Toxicodynamics (TD), 438–439
- Toxicogenetics, ix
- Toxicogenomics, 435–436
risk assessments and, 379
- Toxicokinetics (TK), 93, 438
- Toxicology, microarray technology and, 48
- Toxicology research, mechanistic, 439
- Toxicoproteomics, 435–436

- Toxic oxidized lipids, metabolism of, 161
- Toxic responses, multifaceted nature of, 441
- Toxic tort litigation, role of ecogenetics in, 423–425
- Toxin metabolism, butyrylcholinesterase and, 169
- Toyota v. Williams*, 421
- Transcription-coupled nucleotide excision repair, 185
- Transgenic animal bioassays, 433
- Transgenic mice, 14
- Transmission disequilibrium test (TDT), 299–300
- Triglyceride metabolism, 337
- Trihalomethane (THM) byproducts, study of exposure to, 68–69
- Trimethylaminuria (TMAU), 122–123, 124
- TT genotype, 341
- Tuberculosis, 317–318
- Tumor classification, gene expression profiles and, 48
- Tumor necrosis factor alpha (TNF- α), 312–313
- Twin studies
of addiction, 354
for type 2 diabetes, 293–294
- Two-channel microarrays, experimental design for, 42
- Type 1 diabetes, 286
- Type 2 diabetes, 285–301. *See also* Diabetes entries
background of, 285–286
defined, 286
environmental exposures and, 289–290
epidemiology of, 286–289
gene–environment interactions in, 297–300
genetic influences on, 291–293
genetics of, 293–296
linkage and association studies of, 294–295
prevalence of, 288
risk factors for, 288–289
- Tyr113His polymorphism, 27
- Tyramine, 121
- UDP–glucuronosyltransferases (UGTs), 128–132. *See also* UGT entries
UGT1, 130
UGT1A1 polymorphisms, 132
UGT2, 130
UGT glucuronidation reaction, 128f
UGT isoforms, 130–132
UGT polymorphisms, 131t, 349
UGT tissue distribution and substrates, 129t
Umami, 328–329
- Uncertainty factors, 437–438
- United States, diabetes in, 286–288. *See also* Environmental Protection Agency (EPA); Federal entries; Finland–United States Investigation of NIDDM Genetics (FUSION) study; Food and Drug Administration (FDA); National entries
- Valine, 333
- Value-of-information (VOI) analysis, 443
- Variable-number tandem repeats (VNTRs), 26
- Vaughan, Thomas L., xv, 239
- VDR polymorphisms, 341–342
- “Veil of ignorance” decisionmaking, 394
- Ventral tegmental area, 356
- Very-low-density lipoprotein (VLDL), 337
- Vicine, 347–348
- Virtue-based ethical analysis, 388
- Vitamin D, biological effects of, 202
- Vitamin D₃ receptor (VDR), 341–342
- Vitamin D receptor, 201–204
polymorphisms of, 202–204

- Vitamin metabolism, genetic differences in, 340–342
- Warfarin resistance, 10
- Werner syndrome, 193
- Worker's compensation, 418, 419
- Workplace
genetic testing in, 379, 385, 412, 417–423
predictive genetic screening tests in, 405
- Workplace exposures, illness resulting from, 417–418
- Workplace susceptibility testing, 379, 417–423
limits on, 420–423
- WTCOMT gene, 145–146
- Xenobiotic biotransformation enzymes, polymorphisms in, 93
- Xenobiotic conjugation
polymorphisms, 127–158
glutathione *S*-transferases and, 146–154
methyltransferases and, 143–146
- N*-acetyltransferases and, 139–143
NQO1 and NQO2 and, 154–156
sulfotransferases and, 132–139
UDP–glucuronosyltransferases and, 128–132
- Xenobiotic detoxification,
biotransformation in, 95–96
- Xenobiotic-induced disease
DNA methylation and, 33
risk of, 126
- Xenobiotic intrinsic clearance, 99, 100f
- Xenobiotic metabolism, 97–99
CYP3A5 and, 115–116
- Xenobiotic responsive element (XRE), 205
- Xenobiotics, individual response to, 101
- Xeroderma pigmentosa (XP), 193
- Xeroderma pigmentosum
complementation group D (XPD), 231
- XRCC1 gene, lung cancer and, 231
- XRCC1 protein, 184
- Yeung, Catherine K., xv, 95

